top of page

OUR MISSION

To provide affordable access to Biotherapeutics

We strive to provide affordable access to biotherapeutics for all patients. This mission helps us to stay committed to medical needs in under-served areas and support as many people as possible in bringing normalcy to their life (avoid suffering) with our work.

Our Focus

Plain Images - Igynte Pharma - Presentation - Idea Space Master File  (6).png

Plasma Derived Medicines

 We intend to produce drugs for middle east & low-medium income these undertreated regions of the world to help patients treat their conditions."

​

Image by Christoph Schulz

Self Sufficiency for low-medium income countries

Self sufficiency for PDMPs based autoimmune disease treatment is necessary to meet our target markets needs.

Happy Patient

Affordable Access to Biotherapeutics

Our mission and focus to serve medical needs in underserved areas and support as many people as possible in bringing normalcy to their life,

Syringe

"Currently there is limited to no plasma collection and industrial manufacturing capability in low & medium income countries for PDMPs. We intend to produce drug for these undertreated regions of the world to help patients."

The high demand of PDMPs, especially IgG and Albumin is currently dependent on plasma collected from US (65% of world plasma collection) and EU. Zoinova Biopharma aspires to change this. 

​​

Hospital

Bringing Affordable Access to Biotherapeutics

To  low-medium income countries

Plain Images - Igynte Pharma - Presentation - Idea Space Master File  (6).png
samantha-reinders_mariestopes_064-70-97_custom-29586b8c8f281d8872f80c5aee322fda4dc856e9.jp

Self Sufficiency for low-medium income countries

Self sufficiency for PDMPs based autoimmune disease treatment is necessary to meet individual countries needs. Dependency on any country can cause havoc in supply reliability in case of natural disasters (e.g. pandemic), geopolitical situations (e.g. war) or any other unimaginable risks. Increasing geriatric population and immune deficiency diseases further stresses need for countries to become self reliant.

 

1.png
Abstract Architecture

OUR VISION

'To bring happiness into the life of people we touch and to be driven by humanity"

processing of plasma is not only equipment but people as experts till caregivers and patients who are our customers and beneficiaries.

The Global Albumin Market is expected to reach 

$21

BILLION

USD

BY

2030

INDUSTRY

Our Partners

The work we do in plasma business starts with people such as donors, technicians, doctors, regulators and investors. We aspire to bring happiness to all we connect with while focusing humanity as our driver we will be successful in achieving our mission. 

People we connect with such as donors, technicians, doctors, regulators, colleagues, investors and other stakeholders.

​

Business with humanity as our motto and driver - and this will bring success in achieving our mission.

1.png

DONORS

2.png

DOCTORS

3.png

TECHNICIANS

4.png

REGULATORS

bottom of page